Shire completes $5.9B buyout of Dyax; FDA approves Botox for treating lower limb spasticity;

@FiercePharma: Veterinarian turns dog owner's tragedy into cloud-based EHR for pets. More | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Story | Follow @EricPFierce

@CarlyHFierce: Glaxo CEO: Consumer health can stand on its own, but don't expect a quick spinoff. Article | Follow @CarlyHFierce

> Shire ($SHPG) today said it had completed its $5.9 billion buyout of Massachusetts-based Dyax, a buy that it says could bring $2 billion in sales. Release

> Allergan ($AGN) says the FDA has approved Botox for the treatment of lower limb spasticity in adult patients to decrease the severity of increased muscle stiffness in ankle and toe muscles. Release

> Sun Pharmaceutical has gotten approval from the Competition Commission of India to sell two marketing divisions to Strides Shasun. Story

Medical Device News

@FierceMedDev: Video game neuro therapy company Akili Interactive raises $30M+. More | Follow @FierceMedDev

@EmilyWFierce: Shkreli's 5th Amendment hall pass rejected for congressional drug pricing hearing. Story | Follow @EmilyWFierce

> Mayo Clinic dispatches UV-emitting robots to fight drug-resistant bacteria. More

> St. Jude recalling some defibrillator leads due to poor insulation. Story

Biotech News

@FierceBiotech: Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters. Story | Follow @FierceBiotech

@JohnCFierce: You've got to have a code for Twitter: Rule #1. If you want to poke at me, fine. But if you're anonymous, you get blocked. #comeoutandplay. | Follow @JohnCFierce

@DamianFierce: The $SRPT cancellation robbed us of a situation in which Ed Kaye and Janet Woodcock are trapped in White Oak and have to unite to survive. | Follow @DamianFierce

> Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters. Story

> Astellas is still struggling to close its $379M Ocata buyout. Article

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.